Serum C1q- binding adiponectin in maintenance hemodialysis patients

BMC Nephrology

Iichiro Shimomura¹  Tohru Funahashi⁴  Hironori Kobayashi³  Hideaki Nakatsuji¹  Masaaki Arima²  Naohiro Kishida²  Ken Kishida² 

[1] Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2–2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan;Kishida Clinic, 5-6-3, Honmachi, Toyonaka, Osaka 560-0021, Japan;Department of Research and Development, Diagnostic Division, Otsuka Pharmaceutical Co., Ltd, Tokushima 771-0195, Japan;Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2–2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan

关键词: C1q-binding adiponectin, Hemodialysis;    C1q;    Adiponectin;   

Others  :  1082988
DOI  :  10.1186/1471-2369-14-50

 received in 2012-09-25, accepted in 2013-02-22,  发布年份 2013

【 摘 要 】

Background

Patients on maintenance hemodialysis (HD) have much higher levels of adiponectin (Total-APN). Adiponectin and C1q form a protein complex in human blood, and serum C1q-binding adiponectin (C1q-APN) can be measured. We recently reported that C1q-APN/Total-APN ratio rather than Total-APN correlated with atherosclerosis in diabetics. However, the characteristics of C1q-APN in HD patients remain unclear. The preset study investigated the characteristics of the adiponectin parameters including C1q-APN and also to clarify the relationship between various serum adiponectin parameters and atherosclerotic cardiovascular diseases (ACVD) in HD patients.

Methods

The single cross-sectional study subjects were 117 Japanese patients (males/females = 61/56) on regular HD. Blood Total-APN, high molecular weight-adiponectin (HMW-APN), C1q-APN and C1q concentrations were measured by enzyme-linked immunosorbent assays. ACVD were defined as stroke, coronary and peripheral artery diseases, thoracic and abdominal aneurysms.

Results

Stepwise regression analysis identified high-density lipoprotein-cholesterol (HDL-C) as the only significant and independent determinant of C1q-APN in males, and duration of HD as the only significant and independent determinant of C1q-APN in females. Stepwise regression analysis identified uric acid, low-density lipoprotein-cholesterol and triglyceride as significant and independent determinants of C1q-APN/Total-APN ratio in males, and leukocyte count and HDL-C as significant and independent determinants of C1q-APN/Total-APN ratio in females. Multiple logistic regression analysis identified inorganic phosphorus and C1q-APN or C1q-APN/C1q ratio as significant determinants of ACVD.

Conclusions

Low serum C1q-APN and C1q-APN/C1q ratio, but not C1q-APN/Total-APN ratio, correlated with ACVD in HD patients.

Trial registration

ClinicalTrials.gov: UMINhttp://000004318 webcite

【 授权许可】

   
2013 Kishida et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1996, 257:79-83.
• [2]Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
• [3]Kishida K, Funahashi T, Shimomura I: Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012, 12:118-131.
• [4]Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
• [5]Nakatsuji H, Kobayashi H, Kishida K, Nakagawa T, Takahashi S, Tanaka H, Akamatsu S, Funahashi T, Shimomura I: Binding of adiponectin and C1q in human serum, and clinical significance of the measurement of C1q-adiponectin / total adiponectin ratio. Metabolism 2013, 62:109-120.
• [6]Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68:975-981.
• [7]Hirata A, Kishida K, Kobayashi H, Nakatsuji H, Funahashi T, Shimomura I: Correlation between serum C1q-adiponectin/total adiponectin ratio and polyvascular lesions detected by vascular ultrasonography in Japanese type 2 diabetics. Metabolism 2013, 62:376-385.
• [8]Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I: High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Metabolism 2012. in press
• [9]Nakatsuji H, Kishida K, Kobayashi H, Funahashi T, Shimomura I: The Senri Study II Group: Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio without changes in body mass index in people with type 2 diabetes. Diabetes Res Clin Pract 2013, 99:e14-e17.
• [10]Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, Okada T, Nakagawa Y, Tamba S, Kuroda Y, Hayashi N, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Funahashi T, Matsuzawa Y, Osaka CAD Group: Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circ J 2008, 72:23-28.
• [11]Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
• [12]Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
• [13]Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 2007, 11:340-348.
• [14]Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T: Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial 2008, 12:42-48.
• [15]Matsubara M, Namioka K, Katayose S: Relationships between plasma adiponectin and blood cells, hepatopancreatic enzymes in women. Thromb Haemost 2004, 91:360-366.
• [16]Kotani K, Hazama A, Hagimoto A, Saika K, Shigeta M, Katanoda K, Nakamura M: Adiponectin and smoking status: a systematic review. J Atheroscler Thromb 2012, 19:787-794.
• [17]Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS, HEMO Study Group: Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008, 23:2619-2628.
• [18]Okano K, Ohba T, Matsugami K, Uchida K, Nitta K, Kabaya T: Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. Intern Med 2008, 47:1379-1386.
• [19]Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, Yamamoto T, Hishida A: Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 2008, 47:485-491.
• [20]Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K: Relationship of high-molecular-weight adiponectin levels to visceral fat accumulation in hemodialysis patients. Intern Med 2010, 49:299-305.
• [21]Abdallah E, Waked E, Nabil M, El-Bendary O: Adiponectin and cardiovascular outcomes among hemodialysis patients. Kidney Blood Press Res 2012, 35:247-253.
• [22]Amira OC, Naicker S, Manga P, Sliwa K, Mia A, Raal F, Crowther NJ, Immelman RA, Olorunju S: Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int 2012, 16:59-68.
• [23]Dodd NJ, Vergani D, Turney JH, Parsons V, Weston MJ: Complement activation and C1q binding activity in haemodialysis. Proc Eur Dial Transplant Assoc 1981, 18:300-304.
• [24]Inoshita H, Ohsawa I, Kusaba G, Ishii M, Onda K, Horikoshi S, Ohi H, Tomino Y: Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis. BMC Nephrol 2010, 11:34. BioMed Central Full Text